1. Heneghan C, Goldacre B, Mahtani KR. Why clinical trial outcomes fail to translate into benefits for patients. Trials. 2017;18(1):122.
2. European Commission Inventory of Union and Member State incentives to support research into, and the development and avalaibility of, orphan medicinal products - state of play 2015: European Commission; 2016.
3. Morel T, Lhoir A, Picavet E, et al. Regulatory watch: the orphan drug pipeline in Europe. Nat Rev Drug Discov. 2016;15(6):376.
4. US Food and Drug Administration (FDA). The Rise in Orphan Drug Designations: Meeting the Growing Demand. FDA Voice, 18/07/2016. http://blogs.fda.gov/fdavoice/index.php/2016/07/the-rise-in-orphan-drug-designations-meeting-the-growing-demand/ . Accessed 01 June 2017.
5. Cortelis Regulatory Intelligence. Clinical trial data seen as inadequate to support approval for Sarepta's DMD treatment. AdComm Bulletin, 2016.